FY2027 EPS Estimate for Compass Therapeutics Cut by Analyst

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Wedbush decreased their FY2027 earnings estimates for shares of Compass Therapeutics in a research report issued to clients and investors on Thursday, May 8th. Wedbush analyst R. Driscoll now expects that the company will earn $0.33 per share for the year, down from their prior forecast of $0.42. Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ FY2028 earnings at $1.00 EPS.

Other equities research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Guggenheim dropped their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $13.13.

Compass Therapeutics Stock Up 10.4%

NASDAQ:CMPX opened at $2.01 on Monday. The company has a market cap of $277.95 million, a PE ratio of -5.43 and a beta of 1.40. The business’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12).

Hedge Funds Weigh In On Compass Therapeutics

Large investors have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. SG Americas Securities LLC lifted its position in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares during the period. Renaissance Technologies LLC boosted its stake in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock valued at $404,000 after purchasing an additional 56,000 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in Compass Therapeutics by 250.7% during the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after purchasing an additional 28,589 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after purchasing an additional 227,864 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction on Monday, April 7th. The shares were acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 28.50% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.